Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by BehStreet on Jun 09, 2020 3:56pm
310 Views
Post# 31130320

RE:Transparency

RE:TransparencyThe "Korean" trial is being run by an indepependent CRO, Novotech, and, as stated in the webinar last week, Novotech won't divulge information until the trial has completed. I have already explained why patient enrollment is behind in South Korea, see my previous posts. As for the "Canadian" trial, it hasn't started yet. It is part* of the phase 2b/3 trial "international" trial, along with the U.S. and originally Australia (AUS might now be out). They just go FDA approval last week, it takes time recruiting for a trial, and you need approval first. Here's a link that might help you with your due diligence, if you read carefully, you might be surprised what you find.

https://clinicaltrials.gov/ct2/show/NCT04382924

Justforfun10 wrote: If patient enrollment has not started in the Korean and Canadian trials I think the company needs to explain why? How difficult is it to administer 3 pills per day? Are patients opting for other treatments such as Remdisivir? Are they waiting for the successful development of the IV formulation? Each week that passes by without enrollment is burning available funds.


<< Previous
Bullboard Posts
Next >>